Wednesday, June 24, 2009
WEDNESDAY, June 24 (HealthDay News) -- In a phase II clinical trial, treatment with docetaxel and capecitabine dramatically reduced prostate-specific antigen (PSA) levels in a cohort of patients with metastatic, castrate-resistant prostate cancer (CRPC), according to a report in the July issue of the Journal of Urology.
Ulka N. Vaishampayan, M.D., of Wayne State University in Detroit, and colleagues recruited a cohort of 30 patients (mean age of 69 years) with CRPC for the phase II trial. The patients were treated in 28-day cycles according to a variable schedule with intravenous docetaxel (36 mg/m2 per week) and oral capecitabine (1,250 mg/m2 per day). Patient response was assessed after every two treatment cycles and changes in PSA levels were noted.
According to the study authors, the therapy resulted in a 50 percent or greater decrease in PSA in 22 patients, with nine of those patients having a 90 percent or more decrease. In terms of outcomes, median time to disease progression in the group was 6.7 months, and median overall survival was 22.0 months.
"The combination of docetaxel and capecitabine demonstrated encouraging responses and durable remission in patients with metastatic CRPC in this phase II trial. This could be a stimulus for evaluating this regimen in a larger trial. Future investigations exploring effective tools to individualize therapy are likely to optimize outcome," the authors conclude.
The study was supported by Sanofi-Aventis. Two of the study authors reported financial relationships with Sanofi-Aventis and Asterand.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.